Teladoc Health (TDOC) Now A VALUE STOCK??!!??

TL;DR

Teledoc Health, with a 4.6 billion dollar valuation and 80% decrease in stock value, is showing signs of turning the corner with its financials, making it a potential value stock.

Transcript

so I I can't believe I'm gonna say this with a straight face and actually mean it but is teledoc Health now a value stock after all this time what is going on investors hopefully you guys are doing well out there if you remember my videos on teledoc health they mirrored a little bit of our Intel videos and our plug power videos I absolutely invisce... Read More

Key Insights

• 🥺 Teledoc Health's stock has decreased by over 80% in the past year, leading to a 4.6 billion dollar valuation.
• 💓 The company's Q3 earnings beat expectations, with revenue of 611.4 million dollars and 17% growth year over year.
• 🖕 Despite not being profitable, Teledoc Health's mid-teens revenue growth and improved margins indicate positive prospects.

Questions & Answers

Q: Is Teledoc Health now considered a value stock?

Teledoc Health's significant decrease in market caps, improved financials, and potential for mid-teens revenue growth make it a potential value stock worth considering.

Q: How did Teledoc Health perform in its Q3 earnings?

Teledoc Health reported Q3 revenue of 611.4 million dollars, beating expectations and showing a 17% growth year over year.

Q: What is the Q4 revenue guidance for Teledoc Health?

Teledoc Health expects Q4 revenue between 625 and 640 million dollars, aligning with average analyst estimates.

Q: Is Teledoc Health expected to achieve profitability?

While Teledoc Health is not projected to be profitable in the next two years from a gap perspective, its mid-teens revenue growth and improved financials suggest it is on the path to profitability.

Summary & Key Takeaways

• Teledoc Health reported Q3 earnings of 611.4 million dollars, beating expectations and showing a 17% growth year over year.

• Q4 guidance suggests expected revenue between 625 and 640 million dollars, aligning with average analyst estimates.

• While the company is still not profitable, its mid-teens revenue growth and improved margins indicate positive prospects.